Benzinga

Benzinga

Benzinga

domenica, agosto 23

Zentalis Pharmaceuticals Inc

ZNTLNASDAQ
Trade with Public
Trade with Public
$3.83
-0.015-0.39%
In chiusura: Aug 21, 5:00 PM EST
$3.84
0.01510.39%
Post-mercato: Aug 21, 7:15 PM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

Zentalis Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Zentalis Pharmaceuticals (ZNTL).

Price Target Range — 12 Quarters

Analyst Consensus — 8 Analysts

6Buy
2Hold
Consensus RatingBuy# Analysts8Avg. Consensus PT$9Upside to Avg. PT+122.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 23, 2026Rodman & Renshaw—InitiateBuy$11
Jul 17, 2026MizuhoGraig SuvannavejhInitiateOutperform$8
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Rodman & Renshaw Initiates Coverage On Zentalis Pharmaceuticals with Buy Rating, Announces Price Target of $11

Rodman & Renshaw initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Buy rating and announces Price Target of $11.
Benzinga Newsdesk

PRO
Mizuho Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating, Announces Price Target of $8

Mizuho analyst Graig Suvannavejh initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform rating and announces Price Target of $8.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Zentalis Pharmaceuticals, Raises Price Target to $10

Guggenheim analyst Michael Schmidt maintains Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Buy and raises the price target from $6 to $10.
Benzinga Newsdesk

PRO
Guggenheim Reiterates Buy on Zentalis Pharma, Maintains $6 Price Target

Guggenheim analyst Michael Schmidt reiterates Zentalis Pharma (NASDAQ:ZNTL) with a Buy and maintains $6 price target.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Zentalis Pharma, Lowers Price Target to $4

Morgan Stanley analyst Matthew Harrison maintains Zentalis Pharma (NASDAQ:ZNTL) with a Equal-Weight and lowers the price target from $8 to $4.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Zentalis Pharma, Lowers Price Target to $5

Wells Fargo analyst Derek Archila maintains Zentalis Pharma (NASDAQ:ZNTL) with a Equal-Weight and lowers the price target from $6 to $5.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved